High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel. National Israel Study of Ovarian Cancer

B. Modan, E. Gak, R. B. Sade-Bruchim, G. Hirsh-Yechezkel, L. Theodor, F. Lubin, G. Ben-Baruch, U. Beller, A. Fishman, R. Dgani, J. Menczer, M. Papa and E. Friedman
Department of Clinical Epidemiology, Chaim Sheba Medical Center, Tel Hashomer, Israel.

OBJECTIVE: To determine the role of BRCA1 185delAG mutation in ovarian carcinogenesis. DESIGN: Genetic testing of a subset of cases from an ongoing study of ovarian cancer and of controls. SETTING: A community-based case-control incidence study. SUBJECTS: Seventy-nine patients with ovarian cancer, 62 hospitalized women without cancer (controls), and 120 healthy women participating in a fragile X screening program (also controls), examined for the presence of germline BRCA1 185delAG mutation. MAIN OUTCOME MEASURES: Polymerase chain reaction-amplified BRCA1 exon 2 fragments generated from patients' and controls' blood samples, analyzed by heteroduplex gel shift assay and direct sequence analyses. RESULTS: The 185delAG mutation was detected in 38.9% (7/18) of ovarian cancer patients with familial history, and 13.1% (8/61) of family history-negative ovarian cancer cases. Only 1 carrier was detected among the 120 healthy controls, and none in the hospital controls. A significant difference in mutation carrier rates between family history-negative cases and control groups of 120 and 62 subjects was identified (Fisher exact test, P=.001 and P=.003, respectively). The median age (+/-SE) at disease diagnosis was lower among both familial and family history-negative mutation carriers, as compared with mutation-negative, family history-negative cases--50 (+/-1.4) vs 60.5 (+/-3.5) years old, respectively (hazard ratio, 1.68; 95% confidence interval, 0.94-3.01). CONCLUSIONS: Our data are preliminary but suggest that BRCA1 185delAG germline mutation is frequent in Israeli ovarian cancer patients, irrespective of family history, and may confer an early-onset phenotype of ovarian cancer

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kin-Cohort Study in Ontario, Canada
Risch et al.
JNCI J Natl Cancer Inst 2006;98:1694-1706.
ABSTRACT | FULL TEXT  

Cancer Incidence in a Population of Jewish Women at Risk of Ovarian Cancer
Liede et al.
JCO 2002;20:1570-1577.
ABSTRACT | FULL TEXT  

Parity, Oral Contraceptives, and the Risk of Ovarian Cancer among Carriers and Noncarriers of a BRCA1 or BRCA2 Mutation
Modan et al.
NEJM 2001;345:235-240.
ABSTRACT | FULL TEXT  

BRCA1 Germline Mutations in Women With Uterine Serous Papillary Carcinoma
LAVIE et al.
Obstet Gynecol 2000;96:28-32.
ABSTRACT | FULL TEXT  

Genetically Tailored Preventive Strategies: an Effective Plan for the Twenty-first Century?
Li and Whittemore
Cancer Epidemiol. Biomarkers Prev. 1999;8:649-658.
ABSTRACT | FULL TEXT  

A Population-Based Study of BRCA1 and BRCA2 Mutations in Jewish Women With Epithelial Ovarian Cancer
LU et al.
Obstet Gynecol 1999;93:34-37.
ABSTRACT | FULL TEXT  

BRCA1 Mutations and Survival in Women with Ovarian Cancer
Cannistra et al.
NEJM 1997;336:1254-1257.
FULL TEXT  

BRCA1 Mutation Is Common in Israelis with Ovarian Cancer
JWatch Women's Health 1997;1997:10-10.
FULL TEXT